Related Experiment Video

Updated: Mar 18, 2026

Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease
04:41

Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease

Published on: July 3, 2018

8.7K

Cystatin C: A prognostic marker after myocardial infarction in patients without chronic kidney disease

Leila Abid1, Salma Charfeddine1, Samir Kammoun1

  • 1Cardiology Department, University Hédi Chaker Hospital, Sfax, Tunisia.

Journal of the Saudi Heart Association
|July 1, 2016
PubMed

Insights

Cystatin C, a marker of kidney function, predicts cardiovascular events after myocardial infarction. Higher cystatin C levels correlate with severe coronary artery disease and increased mortality risk in patients with normal renal function.

Area of Science:

  • Cardiology
  • Nephrology
  • Biomarkers

Background:

  • Cystatin C is a reliable endogenous marker of glomerular filtration rate, surpassing serum creatinine.
  • Emerging evidence links cystatin C to atherosclerotic disease.
  • Its prognostic value in acute coronary syndromes (ACS) with normal renal function requires further investigation.

Purpose of the Study:

  • To evaluate the prognostic significance of cystatin C in patients following myocardial infarction.
  • To assess the association between cystatin C levels and coronary artery disease (CAD) severity.
  • To determine if cystatin C predicts adverse cardiovascular outcomes in patients without chronic kidney disease.

Main Methods:

  • Prospective study including 127 patients post-ACS undergoing coronary angiography.
  • Analysis of cystatin C levels in relation to CAD severity (Gensini score) and culprit artery flow (TIMI score).
  • Follow-up for major adverse cardiovascular events and cardiovascular mortality.

Main Results:

  • Cystatin C levels were significantly higher in patients with severe CAD (3-vessel disease, high Gensini score) and correlated with initial TIMI flow.
  • High cystatin C concentrations were associated with adverse outcomes and cardiovascular mortality during follow-up.
  • Cystatin C demonstrated superior predictive value for major adverse cardiovascular events compared to other laboratory markers (AUC = 0.743).

Conclusions:

  • Elevated cystatin C levels indicate increased coronary artery disease severity in ACS patients with normal renal function.
  • Cystatin C is a strong predictor of adverse cardiovascular outcomes and mortality post-myocardial infarction.
  • Cystatin C offers valuable prognostic information beyond traditional markers in this patient cohort.
Abstract

Keywords:
Cardiovascular mortalityCoronary artery diseaseCystatin CMajor adverse cardiovascular eventsMyocardial infarction

More Related Videos

Assessment of Mitochondrial Functions and Cell Viability in Renal Cells Overexpressing Protein Kinase C Isozymes15:43

Assessment of Mitochondrial Functions and Cell Viability in Renal Cells Overexpressing Protein Kinase C Isozymes

Published on: January 7, 2013

18.7K
A Sensitive and Specific Quantitation Method for Determination of Serum Cardiac Myosin Binding Protein-C by Electrochemiluminescence Immunoassay10:12

A Sensitive and Specific Quantitation Method for Determination of Serum Cardiac Myosin Binding Protein-C by Electrochemiluminescence Immunoassay

Published on: August 8, 2013

17.2K

Related Concept Videos

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
1.1K
Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
455
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
715
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
586
Acute Kidney Injury III: Clinical Manifestations01:29

Acute Kidney Injury III: Clinical Manifestations

Acute Kidney Injury (AKI) progresses through distinct clinical phases: the oliguric, diuretic, and recovery phases, each marked by unique manifestations and challenges.Oliguric Phase:The oliguric phase is the initial stage of AKI, typically lasting 10 to 14 days. This phase is marked by a significant reduction in urine output, usually less than 400 mL per day, indicating decreased kidney function. Fluid retention is a prominent feature, leading to symptoms such as edema, hypertension, and...
1.2K
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
384